Valerio Therapeutics

XPAR:ALVIO (France)  
€ 0.08 (-5.06%) Dec 24
At Loss
P/B:
3.04
Market Cap:
€ 11.55M ($ 12.04M)
Enterprise V:
€ 20.76M ($ 21.65M)
Volume:
38.98K
Avg Vol (2M):
50.88K
Trade In:
Volume:
38.98K
At Loss

Business Description

Description
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.3
Equity-to-Asset 0.14
Debt-to-Equity 3.29
Debt-to-EBITDA -0.82
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.22
Distress
Grey
Safe
Beneish M-Score -2.65
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 46.23
9-Day RSI 49.52
14-Day RSI 48.58
6-1 Month Momentum % -26.01
12-1 Month Momentum % -53.69

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.9
Quick Ratio 0.9
Cash Ratio 0.41
Days Sales Outstanding 324.81
Days Payable 2670.29

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -25.2
Shareholder Yield % -11.59

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 74.75
Operating Margin % -951.03
Net Margin % -1040.66
FCF Margin % -870.09
ROE % -140.41
ROA % -54.29
ROIC % -62.77
ROC (Joel Greenblatt) % -1306.41
ROCE % -77.19
Years of Profitability over Past 10-Year 1

Financials (Next Earnings Date:2025-04-19 Est.)

XPAR:ALVIO's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Valerio Therapeutics Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 1.889
EPS (TTM) (€) -0.14
Beta 2.75
Volatility % 47.48
14-Day RSI 48.58
14-Day ATR (€) 0.004222
20-Day SMA (€) 0.07377
12-1 Month Momentum % -53.69
52-Week Range (€) 0.065 - 0.167
Shares Outstanding (Mil) 153.97

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Valerio Therapeutics Filings

Filing Date Document Date Form
No Filing Data

Valerio Therapeutics Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Valerio Therapeutics Frequently Asked Questions

What is Valerio Therapeutics(XPAR:ALVIO)'s stock price today?
The current price of XPAR:ALVIO is €0.08. The 52 week high of XPAR:ALVIO is €0.17 and 52 week low is €0.07.
When is next earnings date of Valerio Therapeutics(XPAR:ALVIO)?
The next earnings date of Valerio Therapeutics(XPAR:ALVIO) is 2025-04-19 Est..
Does Valerio Therapeutics(XPAR:ALVIO) pay dividends? If so, how much?
Valerio Therapeutics(XPAR:ALVIO) does not pay dividend.

Press Release

Subject Date
No Press Release